Clinical Overview
CHA₂DS₂-VASc is a bedside decision-support calculation used to standardize a defined part of clinical assessment. It estimates stroke and systemic embolism risk in non-valvular atrial fibrillation from common clinical characteristics. The result should be interpreted with the patient’s presentation, baseline function, serial observations, laboratory method, medication exposure, and the protocol used by the treating institution. It is an aid to communication and risk stratification rather than an independent diagnosis or treatment order.
Enter contemporaneous values and confirm every unit before calculating. When physiology is changing, repeat assessment and prioritize the clinical trajectory over a single number. Document the input values alongside the result so another clinician can reproduce the calculation and recognize assumptions. Thresholds describe populations and do not remove the need to investigate discordant symptoms, examination findings, imaging, or biomarkers.
When to Use
- Adults with documented atrial fibrillation or flutter when assessing thromboembolic risk
- Periodic reassessment as age and comorbidities change
Limitations & Safety
Female sex alone is generally treated as a modifier; contemporary guidelines differ in exact treatment thresholds. Validation cohorts, case mix, prevalence, and treatment era affect observed event rates. Pregnancy, extremes of age or body composition, critical illness, and major comorbidity may reduce transportability unless specifically represented in the original model. Do not extrapolate beyond the stated population or substitute this estimate for a validated local pathway.
Before acting, check for missing data, measurement error, competing diagnoses, contraindications, and time-sensitive emergencies. A low-risk label never overrides clinician concern; a high-risk label does not prove the target condition. Discuss consequential decisions with the appropriate senior or specialty team and use current regional guidance.
- Not a bleeding-risk score or a substitute for anticoagulation guidance
- Not designed for mechanical valves or moderate-to-severe rheumatic mitral stenosis
Formula / Scoring Criteria
CHA₂DS₂-VASc = CHF 1 + Hypertension 1 + Age ≥75 2 + Diabetes 1 + Stroke/TIA/embolism 2 + Vascular disease 1 + Age 65–74 1 + Sex category female 1
Interpretation
- 0 male / 1 female — Very low: No non-sex risk factors. Usually no antithrombotic therapy solely for AF stroke prevention.
- 1 male / 2 female — Intermediate: One non-sex risk factor. Consider anticoagulation using current guideline and patient preferences.
- ≥2 male / ≥3 female — Elevated: Multiple stroke-risk factors. Anticoagulation is generally recommended unless contraindicated.
Evidence & References
- Lip GYH, et al. Refining clinical risk stratification for predicting stroke in atrial fibrillation. Chest. 2010.
- 2024 ESC Guidelines for management of atrial fibrillation.
Clinical FAQs
Does female sex alone require anticoagulation?
Usually no. It is commonly treated as a risk modifier when another non-sex risk factor is present.
Should the score be recalculated?
Yes. Age, hypertension, diabetes, vascular disease, and heart failure status may change.
Does the score apply to mechanical valves?
No. Mechanical valves and rheumatic mitral stenosis follow condition-specific anticoagulation guidance.